Čeština
English8-Azapurines as new inhibitors of cyclin-dependent kinases
Havlíček, Libor; Fuksová, Květoslava; Kryštof, Vladimír; Orság, Martin; Vojtěšek, B.; Strnad, Miroslav
BIOORGANIC AND MEDICAL CHEMISTRY 13 [8]: 5399-5407, 2005
Klíčová slova: CDK2; Inhibitor; Anticancer drug
Abstrakt: Purine inhibitors of cyclin-dependent kinases (CDK) seem to be a potential anticancer drug candidate as one of the first representatives, roscovitine, is passing Phase II clinical trials for cancer and glomerulonephritis. In this article, we describe a novel modification of the purine scaffold influencing CDK2 inhibitory activities as well as anticancer properties in cell lines of different histopathological origin. The introduced N at position 8 of the purine ring generally lowered CDK2 inhibitory activity of new 8-azapurines (1,2,3-triazolo[4,5-d]pyrimidines) in comparison to the model trisubstituted purines, whereas the antiproliferative potential of some derivatives remained very high, reflecting their ability to activate p53 tumor suppressor.
DOI:
Autoři z ÚEB: Libor Havlíček, Miroslav Strnad
BIOORGANIC AND MEDICAL CHEMISTRY 13 [8]: 5399-5407, 2005
Klíčová slova: CDK2; Inhibitor; Anticancer drug
Abstrakt: Purine inhibitors of cyclin-dependent kinases (CDK) seem to be a potential anticancer drug candidate as one of the first representatives, roscovitine, is passing Phase II clinical trials for cancer and glomerulonephritis. In this article, we describe a novel modification of the purine scaffold influencing CDK2 inhibitory activities as well as anticancer properties in cell lines of different histopathological origin. The introduced N at position 8 of the purine ring generally lowered CDK2 inhibitory activity of new 8-azapurines (1,2,3-triazolo[4,5-d]pyrimidines) in comparison to the model trisubstituted purines, whereas the antiproliferative potential of some derivatives remained very high, reflecting their ability to activate p53 tumor suppressor.
DOI: